On August 18, 2010, the 27^thNational Pharmaceutical Industry Information Annual Meeting & the 1^stNational Pharmaceutical Industry Top 100 Conference opened in Shanghai. 13 pharmaceutical enterprises in Jiangsu Province including Yangtze River Pharmaceutical Group (YRPG), Heng Rui Medicine, Simcere Pharmaceutical Co., and Chia Tai-Tianqing Pharmaceutical Co. were on this ranking list, among which YRPG ranks 1^st. Xu Haoyu, Vice President of YRPG, was invited and gave a keynote speech.
The annual meeting was hosted by Shanghai Institute of Pharmaceutical Industry and National Pharmaceutical Technical Market Association and undertaken by Information Center of National Pharmaceutical Industry. The selection basis is China Pharmaceutical Statistics Annual Report, which is the only official statistics to reflect the economic situation of national pharmaceutical industry as well as the only official data sources of manufacturing enterprises. According to the sales revenue of 2009, the host first publicized the list of National Pharmaceutical Industry Top 100 and selected the Best R&D Product Line and Most Investment Enterprise Value. Besides ranking Top 1, YRPG was also awarded 2010 Top 10 Enterprises with Best R&D Product Line.
With the theme of "Promoting innovation and increasing brand value" and with a three-perspective analysis of macro policies, enterprises development strategies, selection and development of new products and interpretation and prediction of end-user market, officials and experts from departments concerned and elite from famous pharmaceutical enterprises analyzed price policy, centralized procurement and market characteristics under new medical reform.
Jiangsu is a major producer of pharmaceutical products. At present there are more than 800 pharmaceutical research institutes and 461 pharmaceutical manufacturers. It has taken initial shape of three pharmaceutical sectors: Suzhou-Wuxi-Changzhou Pharmaceutical Industry Group, Nanjing Medicine Valley in southern Jiangsu, China (Taizhou) Medical City in central Jiangsu and Lianyungang New Pharmaceutical Industry Base in northern Jiangsu. 13 pharmaceutical enterprises in Jiangsu are on the list of National Pharmaceutical Industry Top 100. In 2009, the sales revenue of Chinese Pharmaceutical Industry was 957.48335 billion yuan, while the total sales revenue of Jiangsu pharmaceutical industry exceeded 100 billion Yuan for the first time, reaching 124.18480 billion Yuan, increasing by 28% over last year. In addition, Jiangsu's economic indicators continue to lead the country.
As the pioneer pharmaceutical enterprise in Jiangsu Province, YRPG insists on development through innovation, accelerating transformation of development mode, research and development on both Traditional Chinese Medicine (TCM) and western medicine, and striving to develop TCM. Jingqianping Granules, domestic exclusive variety, has won the 2nd National Science and Technology Progress Prize; Lanqin Oral Solution, its competitive product, has been acknowledged as the preferred Chinese patent medicine to treat and prevent hand, foot and mouth disease by State Administration of Traditional Chinese Medicine. Besides, there are another 7 TCM products on the list of national protected varieties. Driven by scientific and technological innovation, YRPG has enhanced comprehensive competitiveness and capacity of sustainable development. In 2009, YRPG’s sales revenue was 18.03 billion Yuan, in spite of the severe domestic and international economic situation.
In recent years, YRPG has attached great importance to independent innovations and product structural adjustment, and put biological pharmacy and TCM internationalization as its key development priorities. Meanwhile, YRPG has started to develop innovative medicines by cooperation with scientific research institutes from countries such as Cuba, America and Netherlands. YRPG is actively building a technology innovation platform, introducing overseas talents, improving independent innovation ability, and accelerating research and development. From January to July of this year, YRPG’s sales revenue kept growing, its overall scale kept expanding, and its quality and profits reached new high.